NVAX | Ticker Profile - Titan Protect

NVAX

Novavax, Inc.

Healthcare · Biotechnology · NMS

$9.49

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.8B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-20.44

Based on estimated future earnings — lower means cheaper

Rev Growth

-79.1%

Year-over-year revenue change

Profit Margin

-14.7%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$16.02

+69% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 9 analysts covering this stock

About Novavax, Inc.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

https://www.novavax.com

Country: United States Employees: 749 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.170

Positive but modest risk-adjusted returns

Kelly Fraction

0.0022

Marginal edge — very small allocation suggested

Calmar Ratio

-0.236

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-17.5%

Historical annualised return based on price data

Max Drawdown

-74.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.37

Significantly more volatile than the market

52W High

$11.97

21% below the year high

52W Low

$6.13

55% above the year low

Avg Volume

4,527,957

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

27.7%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.56

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

2.48

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.38

Like current ratio but excludes inventory — stricter test

Gross Margin

27.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-7.2%

Profit from core operations before interest and tax

Free Cash Flow

$59M

Positive — the business generates more cash than it spends

Revenue (TTM)

$596M

Total revenue over the last 12 months

Net Income

$-87,835,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$25.00

Target Median

$16.02

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go